Current opportunities for the treatment of respiratory diseases in paediatric practice
https://doi.org/10.21518/2079-701X-2018-17-132-136
Abstract
Immediacy of the problem of combination therapy of respiratory diseases in paediatric practice is caused by their multifactorial pathogenesis in children and the need to achieve a high clinical effect in the use of drugs at relatively low doses and with minimum risks of serious adverse effects and drug interactions. The fixed-dose combination of salbutamol, bromhexine and guaifenesin produced in the form of tablets and syrup fully meets these requirements, which makes it possible to use it in children and adults with acute, chronic infectious (ARVI, bacterial pneumonia, respiratory tuberculosis, etc.) and non-infectious (bronchial asthma, pulmonary cystic fibrosis, primary ciliary dyskinesia, etc.) diseases.
About the Authors
V. N. Drozdov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
S. Yu. Serebrova
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University);
Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
O. А. Vorobyeva
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
A. K. Starodubtsev
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
O. V. Dobrovolsky
Central Clinical Hospital of Civil Aviation
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Anoshkina EV, Gammel IV, Kononova SV. Dynamics of respiratory disease morbidity of the child population in the country. Meditsinskiy Almanakh, 2018, 3 (54).
2. Volkov KS, NamazovaBaranova LS, Alekseeva AA, Barannik VA, Tomilova AYu, Vishneva EA, Efendiyeva KE, Muradova OI. Cough in children: etiology, diagnostic features and approaches to therapy. VSP, 2014, 2.
3. Chang AB. Cough. Pediatr Clin North Am, 2009, 56(1): 19-31. ix. doi: 10.1016/j.pcl.2008.10.002.
4. Shields MD, Thavagnanam S. The difficult coughing child: prolonged acute cough in children. Cough, 2013, 10, 9(1): 11. doi: 10.1186/17459974-9-11.
5. Seto WH, Conly JM, Pessoa-Silva CL et al. Infection prevention and control measures for acute respiratory infections in healthcare settings: an update. East Mediterr Health J, 2013, 19(Suppl. 1): 39–47.
6. Kupchenko AN, Ponezheva ZhB. Modern principles of diagnosis and treatment of ARVI. Arkhiv Vnutrenney Meditsiny, 2016, 1 (27).
7. Ivanov NA. Recurrent bronchial obstruction and bronchial asthma in children during the first five years of life. Ros Vestn Perinatol i Pediat, 2016, 5.
8. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Eng J Med, 2010, 363: 2233–47.
9. Simonova OI, Gorinova YuV, Alekseeva AA, Tomilova AYu. Bronchial obstruction syndrome in children: a new solution to an old problem. VSP, 2015, 2.
10. Mizernitsky YuL. Differential diagnosis and differentiated therapy of acute bronchial obstruction in acute respiratory viral infections in young children. PM, 2014, 9 (85).
11. Kosenko IM. Cough in children: a rational approach to the treatment // VSP. 2013. No.1.
12. Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev, 2004, 18(4): CD001831. doi: 10.1002/14651858.CD001831.pub2.
13. Woo V. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. Int J Clin Pract, 2015 Dec, 69(12): 1427-37. doi: 10.1111/ijcp.12720.
14. GRLS – State Register of Medicinal Products. Official website: https://grls.rosminzdrav.ru.
15. Klyachkina IL. Early treatment of cold: prevention of post-infectious cough. RMJ, 2016, 24 (16): 1051-1058.
16. Samsygina GL. Treatment of cough in children. Pediatriya. Zhurnal im. G.N. Speranskogo, 2004, 3
17. Bergogne-Berezin E, Pierre J, Dournovo P. Effect of mucolytic agent (Bromhexine) on the passage of erythromycin into the bronchial secretions. Therapie, 1979, 34: 705–11.
18. Knyazheskaya NP, Bokov EV, Tatarsky AR. The combined drug Ascoril in the treatment of cough and bronchial obstruction. RMJ, 2013, 21 (7): 368-372
19. Dicpinigaitis PV, Gayle YE. Effect of guaifenesin on cough reflex sensitivity. Chest, 2003, 124(6): 2178-81. PMID: 14665498.
20. Meshcheryakov VV, Sinevich OYu, Pavlinova EB, et al. Efficacy and safety of the oral form of saltbutamol (as exemplified by Ascoril) in the treatment of bronchial asthma exacerbations in children. Pediatriya, 2003, 6: 68–70.
21. Fedoseev GB. Zinakova MK. Rovkina EI. Clinical aspects of the use of Ascoril in the pulmonary clinic. Novye Sankt–Peterburgskie Vrachebnye Vedomosti, 2002, 2: 64–67.
22. Prabhu Shankar S, Chandrashekharan S, Bolmall CS, Baliga V. Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. J Indian Med Assoc, 2010 May, 108(5): 313-4, 316-8, 320.
23. Ovchinnikov AYu, et al. Possibilities of cough therapy for ARVI in otolaryngology practice. Vestnik Otorinolaringologii, 2014, 2: 86-89
24. Jayaram S, Desai A. Eficacy and safety of Ascoril expectorant and other cough formula in the treatment of coughmanagement in paediatric and adult patients–a randomised double-blind comparative trial. J Indian Med Assoc, 2000 Feb, 98(2): 68-70.
25. Nurgozhin TS, Gulyaev AE, Ermekbaeva BA, Zhaugasheva SK, Abuova GT, An EA. Results of international multicenter noninterventional clinical study of the efficacy and safety of Ascoril expectorant for the treatment of cough conducted in the Republic of Kazakhstan and in the Republic of Uzbekistan. Klinicheskaya Meditsina, 2013, 6.
Review
For citations:
Drozdov VN, Serebrova SY, Vorobyeva OА, Starodubtsev AK, Dobrovolsky OV. Current opportunities for the treatment of respiratory diseases in paediatric practice. Meditsinskiy sovet = Medical Council. 2018;(17):132-136. (In Russ.) https://doi.org/10.21518/2079-701X-2018-17-132-136
Views:
782
Email this article 